Management of the Cellular Ischemic Phase of Hemorrhagic Shock
The cellular ischemic phase of hemorrhagic shock requires immediate restoration of organ perfusion through controlled fluid resuscitation with warmed blood and blood components, active patient warming, aggressive coagulopathy prevention, and rapid surgical hemorrhage control—all while maintaining permissive hypotension (MAP ≥65 mmHg or systolic BP 80-90 mmHg) until bleeding is definitively stopped 1.
Immediate Resuscitation Strategy
Hemodynamic Targets During Active Bleeding
The critical distinction in managing the cellular ischemic phase is recognizing that normal blood pressure is NOT the goal during active hemorrhage. Permissive hypotension prevents exacerbation of bleeding while maintaining minimal organ perfusion 1. Target a systolic blood pressure of 80-90 mmHg or MAP ≥65 mmHg until surgical control is achieved 2, 3.
Important caveat: This permissive hypotension strategy is contraindicated in traumatic brain injury and spinal cord injury, where adequate cerebral perfusion pressure is mandatory 2. Elderly patients and those with chronic hypertension also require careful consideration of higher targets.
Fluid Resuscitation Protocol
Primary resuscitation fluid should be warmed blood and blood components, NOT crystalloids alone 1. The sequence of blood product availability dictates initial therapy:
- Group O blood (fastest availability)
- Group-specific blood (intermediate)
- Cross-matched blood (when time permits)
If crystalloids must be used initially, administer 0.9% sodium chloride or balanced crystalloid solutions 3. Avoid hypotonic solutions like Ringer's lactate in severe head trauma 3. Restrict colloid use due to adverse effects on hemostasis 3.
Temperature Management
Active warming is mandatory and non-negotiable 1. The cellular ischemic phase rapidly progresses to the lethal triad of hypothermia, acidosis, and coagulopathy 4. Specific interventions include:
- Warm ALL intravenous fluids and blood components to 37°C using approved blood warming equipment 1
- Actively warm the patient using external warming devices
- Never improvise warming methods (no microwaves, radiators, or warm water baths) 1
Coagulopathy Prevention and Management
Early Component Therapy
Anticipate and prevent dilutional coagulopathy through early fresh frozen plasma (FFP) administration 1. The cellular ischemic phase triggers multiple coagulation disturbances beyond simple dilution 4:
- Complement activation (C3a, C5a)
- Neutrophil-mediated tissue injury
- Endothelial glycocalyx degradation
- Mitochondrial dysfunction
Fibrinogen Monitoring
Fibrinogen level is the most sensitive early marker of developing coagulopathy 1. Target fibrinogen >1.5 g/L during massive hemorrhage 1. Use Clauss fibrinogen measurement only—derived fibrinogen values are misleading and should not be used 1.
Tranexamic Acid Administration
Administer tranexamic acid early: 1 g IV over 10 minutes, followed by 1 g over 8 hours 1. This blocks the accelerated fibrinolysis that occurs during the cellular ischemic phase, particularly in trauma, obstetric hemorrhage, and major organ surgery 1.
Surgical Hemorrhage Control
Surgery must be considered early and may require damage control approach 1. The cellular ischemic phase cannot be reversed without definitive bleeding control 5. Surgery may need to be interrupted and limited to temporary hemorrhage control, with definitive repair delayed until physiologic derangements are corrected 1.
Alert the surgical team immediately about cell salvage autotransfusion needs 1.
Monitoring During the Cellular Ischemic Phase
Clinical Assessment
Continuously assess:
- Skin color and capillary refill
- Heart rate
- Blood pressure
- Conscious level
- Obvious blood loss (clothing, floor, drains)
- Signs of internal bleeding 1
Laboratory Monitoring
Obtain baseline and serial measurements:
- Full blood count
- PT and aPTT
- Clauss fibrinogen (not derived)
- Cross-match
- Near-patient testing (TEG/ROTEM if available) 1
Vasopressor Use: A Critical Decision Point
Avoid vasopressors during initial resuscitation 1. However, if severe hypotension with systolic BP <80 mmHg persists despite fluid resuscitation and represents life-threatening shock, transient noradrenaline may be used to maintain life and tissue perfusion 3. This represents a shift from earlier absolute contraindications, recognizing that severe hemorrhagic shock involves a vasodilatory phase requiring temporary vasopressor support 3.
Transition to Definitive Management
Once bleeding control is achieved, aggressively normalize:
- Blood pressure (now target normal values)
- Acid-base status (pH >7.2)
- Temperature (normothermia)
- Calcium levels (normocalcemia) 1, 6
The cellular ischemic phase transitions to reperfusion injury once circulation is restored 4. This involves inflammatory cascades, reactive oxygen species production, and endothelial dysfunction that require critical care monitoring 4.
Post-Resuscitation Care
Transfer to critical care for:
- Continuous hemodynamic monitoring
- Serial coagulation studies
- Hemoglobin monitoring
- Blood gas analysis
- Drain output assessment 1
Initiate venous thromboprophylaxis as soon as bleeding is controlled, as patients rapidly develop a prothrombotic state 1.